Omzo vs Maximus: Compounded Semaglutide Plans Compared

Quick verdict: For clinician-guided, personalized compounded semaglutide and tirzepatide with starting pricing disclosed, Omzo emphasizes licensed provider review and broader medication options; for a lower flat monthly price and straightforward telemedicine access to compounded semaglutide, Maximus lists $132.99 per month and uses trusted U.S. pharmacies.

Explore Omzo clinician-guided plans

Omzo vs Maximus: overview of core differences

This comparison focuses on the most distinctive differences supported by the sources: pricing model and starting price, clinician guidance and prescribing approach, medication options including tirzepatide and branded prescriptions, pharmacy sourcing and shipping, and regulatory notes about compounded drugs.

Pricing model and starting price

Omzo presents pricing with specific starting levels: semaglutide starting at $179 and tirzepatide starting at $279, describing personalized, clinician-guided programs. Maximus presents a lower flat-rate telemedicine option, advertising $132.99 per month for compounded semaglutide and additional mentions of rates like $79.99/month or other starter figures on landing content. Maximus emphasizes a direct-pay monthly rate and transparent pricing.

View Maximus monthly pricing

Clinician guidance and prescribing approach

Omzo connects users with licensed U.S. providers who review plans and make prescribing decisions; Omzo clarifies clinical services are provided by third party networks and providers determine eligibility and prescriptions. Maximus likewise uses licensed doctors approving prescriptions via telemedicine, with no in-person visits required. The distinguishing emphasis is Omzo advertising clinician-guided, personalized plans while Maximus markets convenient telemedicine and a simple direct-pay model.

See Omzo provider review process

Medication options and branded prescriptions

Omzo describes a Compounded Medication Program as its primary program, providing access to compounded semaglutide and tirzepatide and notes compounded drugs are not FDA-approved. Omzo also states providers may write prescriptions for branded medications such as Ozempic or Wegovy, but Omzo does not sell or ship branded drugs and patients are responsible for filling those prescriptions. Maximus focuses on compounded semaglutide and its materials note compounded medication only, with limited published detail on tirzepatide availability.

Pharmacy sourcing, shipping and availability

Omzo says its compounded medications are prepared and shipped by a state-licensed sterile compounding pharmacy and that compounding partners are FDA-registered facilities but the compounded products themselves are not FDA-approved. Omzo also highlights fast, discreet delivery and FSA and HSA eligibility. Maximus fills prescriptions through trusted U.S. pharmacies, advertises free priority or expedited shipping, and states its Weight Loss Protocol is available in all 50 states except Mississippi per captured content.

Regulatory and safety notes

Both sources include a regulatory note that compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Omzo specifically repeats that compounded drugs are not FDA-approved and that providers determine eligibility and prescription decisions. Maximus also states its medication is compounded and not an FDA-approved finished product while noting prescriptions are approved by licensed doctors.

Side-by-side snapshot

What the sources do not supply

The captured evidence does not supply comparative long-term outcomes, detailed patient support or full state-by-state enrollment limits beyond Maximus noting one state exception, nor does it provide comprehensive refund, cancellation or membership terms for both providers beyond the statements shown.

Compare Maximus telemedicine access

Final guidance: Choose based on priorities

If clinician-guided, personalized programs and explicit mention of tirzepatide options matter to you, choose Omzo. If the primary priority is a lower flat monthly price with straightforward telemedicine prescriptions filled through trusted U.S. pharmacies, choose Maximus.

Decide on Omzo clinician-guided care

Omzo vs Maximus: use Omzo if you want clinician-reviewed, personalized compounded GLP-1 programs and access to tirzepatide options; use Maximus if you want the lower flat-rate, direct-pay semaglutide telemedicine model.